Table 1.

Distribution and odds ratios with 95% confidence intervals of latent classes, Carolina Breast Cancer Study 3 (2008-2013) by age and race^a

			Race and age, y
			White				Black
	All cases (n=2998)		<50 (n=751)		≥50 (n=752)		<50 (n=741)		≥50 (n=754)
	No.	(%)	No.	(%)	No.	(%)	No.	(%)	No.	(%)
SES/Comorbidity latent classes
Low SES/High comorbidity	1428	(47.6)	134	(9.4)	259	(18.1)	455	(31.9)	580	(40.6)
High SES/Low comorbidity	1570	(52.4)	617	(39.3)	493	(31.4)	286	(18.2)	174	(11.1)
Low vs. high, OR (95% CI)			0.5	(0.4-0.6)	1.0	ref	3.2	(2.5-4.1)	6.2	(4.7-8.1)
Access to care latent classes
Less barriers to care	2514	(84.1)	709	(28.2)	737	(29.3)	482	(19.2)	574	(22.8)
More barriers to care	476	(15.9)	42	(8.8)	15	(3.2)	258	(54.2)	180	(37.8)
Less vs. more, OR (95% CI)			3.3	(1.6-6.4)	1.0	ref	15.3	(7.8-29.9)	7.8	(4.1-15.4)
Tumor Characteristics latent classesb
HR+/HER2−/Node Negative	1091	(36.5)	290	(26.6)	419	(38.4)	117	(10.7)	265	(24.3)
HER2+/Higher Grade	335	(11.2)	86	(25.7)	59	(17.6)	99	(29.5)	91	(27.2)
HR+/HER2−/Larger Tumor/Node Positive	944	(31.6)	259	(27.4)	181	(19.2)	301	(31.9)	203	(21.5)
TNBC/Higher Grade	617	(20.7)	115	(18.6)	90	(14.6)	222	(36.0)	190	(30.8)
HER2+ vs. HR+/HER2−/Node−, OR (95% CI)			2.6	(1.9-3.6)	1.0	ref	6.3	(4.3-9.1)	2.0	(1.4-2.8)
HR+ vs. HR+/HER2−/Node−, OR (95% CI)			2.3	(1.5-3.6)	1.0	ref	6.3	(3.9-10.0)	2.6	(2.5-3.8)
TNBC vs. HR+/HER2−/Node -, OR (95% CI)			2.0	(1.5-2.9)	1.0	ref	9.0	(6.1-13.0)	3.4	(2.5-4.6)

Abbreviations: SES, socioeconomic status; HER2+, human epidermal growth factor receptor 2 positive; TNBC, triple negative breast cancer

^aLatent class domains not mutually adjusting for one another

^bN=2987